CCJ · Cameco Corporation

Current Thesis

Cameco’s uranium repricing thesis needs an equity recovery confirmed by delivery execution at the 2026-10-30 results; a weekly close below $85 invalidates that recovery case. The company’s filed results now establish October 30 as the planned reporting date, replacing the estimated date in the September 3 note. Cameco’s July 31 release

The measured update is weaker price momentum despite additional analyst attention: CCJ’s adjusted September 11 close was US$96.68, with its 14-day relative strength index (RSI) at 39.4. Jefferies initiated coverage on September 3 with a C$190 analyst target and linked nuclear demand partly to electricity consumption from artificial intelligence. The inference is that the narrative is maturing — the September 3 initiation extends an established story, while the September 11 close remains below the August 27 close of US$106.33. A weekly recovery above that August close would contradict the assessment of stalled participation. Jefferies initiation coverage

The September 3 note’s comparison between uranium benchmarks and company realizations requires a currency distinction. Cameco reported second-quarter realized uranium prices of C$93.13 per pound and US$67.79 per pound for the period ended June 30. A dollar-denominated benchmark cannot establish delivery economics without matching the currency and contract terms. Filed second-quarter results

Bullish and bearish views on Cameco Corporation

The model's bull view on Cameco Corporation (CCJ), in brief: Production guidance survived operational disruptions. The bear view: Realized pricing did not prevent contraction. Both cases follow in full.

Bull Case

• Production guidance survived operational disruptions. On July 31, Cameco maintained attributable 2026 uranium production guidance of 19.5–21.5 million pounds despite disruptions at Key Lake, McArthur River and Cigar Lake. The execution case would weaken if a subsequent company update reduced that range. Cameco’s second-quarter report
• Contract pricing improved during deliveries. Second-quarter realized uranium prices increased 18% year over year to US$67.79 per pound, according to the July 31 filing. This is measured pricing improvement; continuation would be contradicted by a subsequent quarter reporting a year-over-year decline. Filed second-quarter results
• Fresh coverage extends nuclear attention. Jefferies’ September 3 initiation assigned Cameco a C$190 target. That is the analyst’s valuation opinion; the September 11 market close of US$96.68 does not establish acceptance of it, and the currencies are different. Initiation report

Bear Case

• Realized pricing did not prevent contraction. Cameco reported second-quarter consolidated revenue of C$814 million, down 7% year over year, on July 31. Improved uranium pricing therefore coexisted with lower consolidated sales. Filed second-quarter results
• Analyst attention has outlasted strength. The September 11 adjusted close of US$96.68 remained below the August 21 close of US$102.51 and August 27 close of US$106.33 in the published price record. Those observations establish an unrecovered August advance, without identifying who supplied or withdrew demand.
• Coverage clustering is not positioning. The September 3 Jefferies initiation appeared in Investing.com that day and Defense World on September 4. These are repeated reports of one analyst event; the sample is too small to support a claim about retail crowding or incremental institutional demand. September 4 coverage

Setup & Price Structure

The September 11 adjusted market record shows a US$96.68 close, 27.9% below the US$134.09 trailing annual high, and a three-month price decline of 4.2%. RSI was 39.4. These measurements describe weakness; they do not establish an approaching reversal.

The recovery case requires a weekly close above $106.33, the August 27 reference close, alongside delivery execution at the October results. A weekly close below $85 would instead breach the July support threshold identified in the September 3 published research. Evidence conviction remains low because the September 11 close has not recovered the August reference level; no current moving-average or volume series establishes broader participation.

Catalyst Calendar (next 30 days)

• ~2026-09-30, estimated monitoring point: September month-end uranium benchmarks, following the publication cadence described in the September 3 note. This is a commodity observation window, not a confirmed Cameco announcement; the actual September figures are not yet available.
• 2026-10-30, before markets open: Cameco’s planned third-quarter results, explicitly dated in its July 31 filing. This later event is included because delivery execution is the fundamental test of the recovery thesis. Company reporting schedule

No company-confirmed catalyst within the next 30 days was identified in the reviewed calendar. Cameco events

What Would Change Our Mind

Loss of the previously identified July support would end the recovery thesis: a weekly close below $85 is the observable price condition retained from the September 3 research. Fundamentally, a reduction below the 19.5–21.5 million-pound production range maintained on July 31 would undermine the execution argument. Conversely, a weekly close above $106.33 accompanied by maintained production guidance at the October 30 results would provide the missing price and operating confirmation.

Correlation Notes

Benzinga’s August 25 sector report described a 16% August gain in the VanEck Uranium and Nuclear exchange-traded fund, with Energy Fuels, Uranium Energy and Denison Mines each up over 30%. Its August 28 report also associated mining-stock weakness with Kevin Warsh’s inflation remarks. These dated observations identify sector and macroeconomic channels, but the sample is too small to support a correlation claim.

Cameco is assessed here as a single-name recovery case. The September 11 close below its August 27 reference level does not permit the earlier gains in smaller uranium companies to serve as confirmation of Cameco’s own structure.